Over the past 12 months, 3 insiders at Summit Therapeutics Inc. filed 9 open-market SEC Form 4 transactions on SMMT: 9 purchases worth $74.4M and 0 sales worth $0. Insiders have been net buyers over this period. The most recent filing was on Jun 12, 26.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 12, 26 | Robert W DugganCo-Chief Executive Officer | BUY | 3.81M | $13.12 | $50.0M |
| Jun 4, 26 | Robert W DugganCo-Chief Executive Officer | BUY | 100.0K | $14.60 | $1.5M |
| Oct 21, 25 | Robert W DugganCo-Chief Executive Officer | BUY | 26.7K | $18.74 | $500K |
| Oct 21, 25 | Yu XiaDirector | BUY | 533.6K | $18.74 | $10.0M |
| Oct 21, 25 | Mahkam ZanganehCo-Chief Executive Officer | BUY | 26.7K | $18.74 | $500K |
| Sep 11, 25 | Robert W DugganCo-Chief Executive Officer | BUY | 5.0K | $18.07 | $90K |
| Sep 11, 25 | Mahkam ZanganehCo-Chief Executive Officer | BUY | 5.0K | $18.07 | $90K |
| Sep 10, 25 | Robert W DugganCo-Chief Executive Officer | BUY | 333.4K | $17.68 | $5.9M |
| Sep 10, 25 | Mahkam ZanganehCo-Chief Executive Officer | BUY | 333.4K | $17.68 | $5.9M |
| Mar 27, 24 | Mahkam ZanganehChief Executive Officer | BUY | 34.3K | $3.72 | $128K |
| Mar 26, 24 | Ankur DhingraChief Financial Officer | BUY | 100.0K | $3.75 | $375K |
| Mar 26, 24 | Mahkam ZanganehChief Executive Officer | BUY | 30.0K | $3.75 | $113K |
| Dec 13, 23 | Ankur DhingraChief Financial Officer | BUY | 19.7K | $2.17 | $43K |
| Dec 12, 23 | Mahkam ZanganehChief Executive Officer | BUY | 5.0K | $2.07 | $10K |
| Oct 13, 23 | Manmeet Singh SoniChief Operating Officer | BUY | 2.98M | $1.68 | $5.0M |
| Mar 8, 23 | Mahkam ZanganehCo-CEO & President | BUY | 16.78M | $1.05 | $17.6M |
| Mar 7, 23 | Yu XiaDirector | BUY | 21.52M | $1.05 | $22.6M |
| Mar 7, 23 | Ankur DhingraChief Financial Officer | BUY | 196.4K | $1.05 | $206K |
| Jan 17, 23 | Yu XiaDirector | BUY | 10.00M | $2.51 | $25.1M |
| Aug 16, 22 | Ankur DhingraChief Financial Officer | BUY | 24.7K | $0.97 | $24K |
| Aug 16, 22 | Maky ZanganehCo-CEO & President | BUY | 4.59M | $0.97 | $4.5M |
Over the past 12 months, insiders at Summit Therapeutics Inc. filed 9 open-market purchases worth $74.4M and 0 sales worth $0 on SMMT, which makes them net buyers over the period. The most recent Form 4 was filed on Jun 12, 26.
The largest recent open-market SMMT insider purchase in our data was $50.0M by Robert W Duggan, Co-Chief Executive Officer, filed on Jun 12, 26.
3 different insiders at Summit Therapeutics Inc. filed open-market SEC Form 4 transactions on SMMT over the last 12 months.
InsiderTape plots every SMMT insider buy and sell directly on the price chart and flags new SEC Form 4 filings as they arrive, with cluster detection and buy/sell pressure. The data updates daily from SEC EDGAR.
InsiderTape plots every Summit Therapeutics Inc. insider buy and sell on the price chart, with buy/sell pressure, cluster detection, and alerts the moment new Form 4s hit. Start a free 7-day trial, cancel anytime.
Does it work? In five years of data, insider clusters beat the Russell 2000 about 60% of the time and the CFO's buy was the sharpest signal of all. See the backtest →
START FREE TRIAL →